novo nordisk oral semaglutide fda approval BREAKING: The has approved the first GLP-1 pill for obesity, marking a major milestone in the weight-loss drug market and a potential inflection point for treatment access. The daily pill Novo's Ozempic wins FDA nod

302 Notably, microbial metabolites produced by commensal gut flora can limit pathogenic activities of microglia and astrocytes and suppress CNS inflammation in MS experimental models 303 and can contribute to the induction of specific LAMP1+TRAIL+ astrocytes that limit CNS inflammation by inducing T cell apoptosis

Semaglutide and tirzepatide are contraindicated in women with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 [10]

Limited intake of sources rich in B vitamins, such as meats, leafy greens, and fortified grains, due to selective eating patterns or food sensitivities[40]

[8] [9] Activation of GLP-1 receptors stimulates glucose-dependent insulin secretion, suppresses glucagon release, slows gastric emptying, and reduces appetite via central nervous system pathways

If youre obese and fit, actually (the) risk of death is half of that of someone (who) is normal weight but unfit